182 related articles for article (PubMed ID: 16925156)
1. Emerging therapies in head and neck cancers: EGFR inhibitors.
Held-Warmkessel J
ONS News; 2006; 21(8 Suppl):61-2. PubMed ID: 16925156
[No Abstract] [Full Text] [Related]
2. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Morse L
ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155
[No Abstract] [Full Text] [Related]
3. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Dunsford J
Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
[No Abstract] [Full Text] [Related]
4. Expanding nursing expertise in targeted therapy.
Morse L
ONS News; 2006; 21(8 Suppl):55-6. PubMed ID: 16925153
[No Abstract] [Full Text] [Related]
5. Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
Biedrzycki BA
ONS Connect; 2007; 22(8 Suppl):33-4. PubMed ID: 17824555
[No Abstract] [Full Text] [Related]
6. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies: aiming for the bull's-eye.
Gaguski ME
ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
[No Abstract] [Full Text] [Related]
8. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.
Ouwerkerk J; Boers-Doets C
Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896
[TBL] [Abstract][Full Text] [Related]
9. What kind of rash is it?: deciphering the dermatologic toxicities of biologic and targeted therapies.
Esper P; Gale D; Muehlbauer P
Clin J Oncol Nurs; 2007 Oct; 11(5):659-66. PubMed ID: 17962174
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
King CR
ONS News; 2006; 21(8 Suppl):57-8. PubMed ID: 16925154
[No Abstract] [Full Text] [Related]
11. EGFR-targeted therapy for patients with colorectal cancer: patient management and future directions.
ONS News; 2004; 19(9 Suppl):53-4. PubMed ID: 15478587
[TBL] [Abstract][Full Text] [Related]
12. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
13. Clinical management of EGFRI dermatologic toxicities: the nursing perspective.
Purdom M; Ohinata A
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):29-30. PubMed ID: 18154215
[TBL] [Abstract][Full Text] [Related]
14. Common side effects of anti-EGFR therapy: acneform rash.
Sipples R
Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin's lymphomas: understanding monoclonal antibody therapy.
Hendrix C
ONS News; 2006; 21(8 Suppl):19-20. PubMed ID: 16925135
[No Abstract] [Full Text] [Related]
16. Severe acneiform rash.
Yamamoto DS; Viale PH; Zhao G
Clin J Oncol Nurs; 2004 Dec; 8(6):654-6. PubMed ID: 15637959
[No Abstract] [Full Text] [Related]
17. Targeted cancer. These "smart weapons" hit cancer in novel ways.
Held-Warmkessel J
Nursing; 2008 Sep; 38(9):26-32. PubMed ID: 18719487
[TBL] [Abstract][Full Text] [Related]
18. Manage skin toxicities associated with EGFR inhibitors.
Becze E
ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873
[No Abstract] [Full Text] [Related]
19. Targeted therapies in lung cancer: a tribute to advancements in clinical research.
McGee L
ONS Connect; 2007; 22(8 Suppl):27-8. PubMed ID: 17824552
[No Abstract] [Full Text] [Related]
20. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
Eaby B; Culkin A; Lacouture ME
Clin J Oncol Nurs; 2008 Apr; 12(2):283-90. PubMed ID: 18390464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
